Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Outlook Therapeutics (OTLK) Change in Accured Expenses (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Change in Accured Expenses for 7 consecutive years, with -$295952.0 as the latest value for Q4 2025.

Quarterly Change in Accured Expenses fell 292.47% to -$295952.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 26.34% year-over-year, with the annual reading at $1.7 million for FY2025, 247.79% up from the prior year.
Change in Accured Expenses for Q4 2025 was -$295952.0 at Outlook Therapeutics, down from $354702.0 in the prior quarter.
The five-year high for Change in Accured Expenses was $2.2 million in Q2 2025, with the low at -$994707.0 in Q1 2025.